These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16489373)

  • 1. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.
    Snutch TP
    NeuroRx; 2005 Oct; 2(4):662-70. PubMed ID: 16489373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel series of pyrazolylpiperidine N-type calcium channel blockers.
    Subasinghe NL; Wall MJ; Winters MP; Qin N; Lubin ML; Finley MF; Brandt MR; Neeper MP; Schneider CR; Colburn RW; Flores CM; Sui Z
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4080-3. PubMed ID: 22608964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An orally available Ca
    Kutzsche J; Guzman GA; Willuweit A; Kletke O; Wollert E; Gering I; Jürgens D; Breitkreutz J; Stark H; Beck-Sickinger AG; Klöcker N; Hidalgo P; Willbold D
    Br J Pharmacol; 2024 Jun; 181(12):1734-1756. PubMed ID: 38157867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting N-type and T-type calcium channels for the treatment of pain.
    McGivern JG
    Drug Discov Today; 2006 Mar; 11(5-6):245-53. PubMed ID: 16580601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
    Feldman P; Khanna R
    Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke.
    Yamamoto T; Takahara A
    Curr Top Med Chem; 2009; 9(4):377-95. PubMed ID: 19442208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathic pain: role of voltage-dependent calcium channels.
    Chaplan SR
    Reg Anesth Pain Med; 2000; 25(3):283-5. PubMed ID: 10834784
    [No Abstract]   [Full Text] [Related]  

  • 8. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide leads new class of chronic pain drugs.
    Garber K
    Nat Biotechnol; 2005 Apr; 23(4):399. PubMed ID: 15815650
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development.
    Pexton T; Moeller-Bertram T; Schilling JM; Wallace MS
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1277-84. PubMed ID: 21740292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-type calcium channel blockers: a call for papers.
    Baumrucker SJ
    Am J Hosp Palliat Care; 2005; 22(2):91-2. PubMed ID: 15853084
    [No Abstract]   [Full Text] [Related]  

  • 12. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
    Miljanich GP
    Curr Med Chem; 2004 Dec; 11(23):3029-40. PubMed ID: 15578997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
    Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
    Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elan: ziconotide review focused on off-label uses.
    Narayana AK
    Am J Hosp Palliat Care; 2005; 22(6):408. PubMed ID: 16323709
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthetic Aβ oligomers (Aβ(1-42) globulomer) modulate presynaptic calcium currents: prevention of Aβ-induced synaptic deficits by calcium channel blockers.
    Hermann D; Mezler M; Müller MK; Wicke K; Gross G; Draguhn A; Bruehl C; Nimmrich V
    Eur J Pharmacol; 2013 Feb; 702(1-3):44-55. PubMed ID: 23376566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.
    Wermeling DP
    Pharmacotherapy; 2005 Aug; 25(8):1084-94. PubMed ID: 16207099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N- and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain.
    Yamamoto S; Suzuki Y; Ono H; Kume K; Ohsawa M
    Eur J Pharmacol; 2016 Dec; 793():66-75. PubMed ID: 27823932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-type calcium channel blockers: novel therapeutics for the treatment of pain.
    Schroeder CI; Doering CJ; Zamponi GW; Lewis RJ
    Med Chem; 2006 Sep; 2(5):535-43. PubMed ID: 17017994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological characterization of activation state-dependent Ca(v)2 channel antagonist TROX-1 in spinal nerve injured rats.
    Patel R; Rutten K; Valdor M; Schiene K; Wigge S; Schunk S; Damann N; Christoph T; Dickenson AH
    Neuroscience; 2015 Jun; 297():47-57. PubMed ID: 25839150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.